20 March 2020 - To give people more clarity about what medicines PHARMAC is, or is not, actively considering for funding, it will be making more decisions on inactive applications.

Following public consultation, PHARMAC has made a decision to decline the following funding applications:

• Naltrexone hydrochloride for Henoch-Schonlein purpura
• Dipyridamole  for stroke prophylaxis
• Dipyridamole with aspirin for stroke prophylaxis
• Niacin (nicotinic acid) with laropiprant (extended release) for hypercholesterolaemia and mixed dyslipidaemia
• Prasugrel for percutaneous coronary intervention procedure in patients with diabetes
• Aliskiren for hypertension
• Fenofibrate for hyperlipidemia
• Clindamycin for prophylaxis of haematogenous infection of prosthetic joints during dental interventions
• Golimumab as a second-line TNF inhibitor in ankylosing spondylitis
• Golimumab as a second-line TNF inhibitor in psoriatic arthritis
• Omega-3 fatty acids for augmentation of antipsychotics in schizophrenia
• Everolimus as second line therapy in metastatic renal cell carcinoma
• Octreotide for small intestinal neuroendocrine tumours (SI-NETs), metastatic or unresectable
• Bovine lipid extract surfactant for pulmonary distress
• Ciprofloxacin and hydrocortisone ear drops for chronic suppurative otitis media
• Paediatric oral feed (Neocate Nutra) for food allergies
• Oral supplement 1 Kcal/mL to 2 Kcal/mL (Enprocal) for nutrition supplementation

These applications have been ‘inactive’, meaning that PHARMAC has not been actively undertaking any work to progress the applications for funding.

Read PHARMAC Notification